Overview

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

Status:
Completed

Trial end date:
2014-03-10

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Amiodarone
Dronedarone
Ranolazine